Results 181 to 190 of about 27,201 (202)

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer

Annals of Oncology, 2010
Pierfranco Conte, Giuseppe Capri, J Ro
exaly  

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan

Annals of Oncology, 2007
P J O'Dwyer, D J Kerr, K T Flaherty
exaly  

Lapatinib

Reactions Weekly, 2021
openaire   +1 more source

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

Annals of Oncology, 2012
Stefania Gori, Giulio Metro, Giancarlo Bisagni   +2 more
exaly  

The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats

Cancer Chemotherapy and Pharmacology, 2020
Dorothy Keefe, Daniel Thorpe, Bronwen J Mayo   +2 more
exaly  

RON confers lapatinib resistance in HER2-positive breast cancer cells

Cancer Letters, 2013
Liguang Lou, Haitian Quan, Chengying Xie
exaly  

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

Annals of Oncology, 2011
J -U Blohmer, C Hanusch, Holger Eidtmann
exaly  

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

Investigational New Drugs, 2013
Jan H M Schellens, Kevin Koch, Lot A Devriese   +2 more
exaly  

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

Annals of Oncology, 2011
C D Blanke, H J Lenz, C D Blanke
exaly  

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

Annals of Oncology, 2009
Lee S Schwartzberg, Mark D Pegram, K L Blackwell   +2 more
exaly